GlassScriptPhysician profile
Pooja Bhargava
NPI 1619403128
$2,416.06
in general payments reported to CMS, 2019-2025
23 companies · $1,803 in 2025
The $1,803 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.25 · 2023: $169 · 2024: $420 · 2025: $1,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,392.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $600.98 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $287.80 | 2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $220.80 | 2023-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $216.57 | 2024-2025 | Zepbound, Kisunla, Mounjaro |
| Pfizer INC. | $179.39 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.89 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.99 | 2025 | Jardiance |
| Exact Sciences Corporation | $106.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $103.93 | 2025 | Veozah |
| Eisai INC. | $75.49 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $35.90 | 2025 | |
| C2n Diagnostics, LLC | $34.65 | 2025 | Precivityad2 |
| Takeda Pharmaceuticals U.S.A., INC. | $34.42 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $34.39 | 2025 | Auvelity |
| Viiv Healthcare Company | $23.25 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $20.83 | 2025 | Immunocap |
| Amphastar Pharmaceuticals, INC. | $18.54 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.97 | 2025 | Xifaxan |
| Dynavax Technologies Corporation | $17.36 | 2025 | Heplisav-B |
| Esperion Therapeutics, INC. | $16.87 | 2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $16.80 | 2024 | Quviviq |
| Abbvie INC. | $15.41 | 2024 | |
| Xeris Pharmaceuticals, INC. | $13.67 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Bhargava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.